SCHEMBL243274

SCHEMBL243274

CCOC(=S)c1cnc(C)nc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
KDM4E B2RXH2 2/20 0.43
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.35
NFKB1 P19838 2/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35
FOS P01100 1/20 0.35
JUN P05412 1/20 0.35
DGAT1 O75907 1/20 0.35
MAPT P10636 4/20 0.35
MAPK1 P28482 2/20 0.35
LMNA P02545 1/20 0.35
ATM Q13315 1/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
TP53 P04637 2/20 0.34
CSNK1D P48730 1/20 0.34
CYP1A2 P05177 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5211853 0.83 KDM4E (0.33) ALDH1A1KDM4EKMT2AMEN1LMNA
SCHEMBL9684348 0.83 RAB9A (0.37) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL2022922 0.81 CSNK1D (0.38) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL427402 0.80 ALDH1A1 (0.63) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL4717515 0.80 LMNA (0.44) ALDH1A1KDM4ESMN1; SMN2NFKB1NFKB2
SCHEMBL8399261 0.80 NFKB1 (0.36) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL6621732 0.80 NFKB1 (0.35) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL28520507 0.78 RAB9A (0.36) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL2027032 0.78 ALDH1A1 (0.41) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL27471759 0.77 HTT (0.34) ALDH1A1KDM4EKMT2AMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109694354-B Synthesis method of 4-chloro-2-methylthiopyrimidine-5-ethyl formate 南京哈柏医药科技有限公司 2023-10-24 CN claimed
US-20250304587-A1 WEE1 INHIBITOR, PREPARATION THEREFOR AND USE THEREOF JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) 2025-10-02 US disclosed
EP-4570807-A1 WEE1 INHIBITOR, PREPARATION THEREFOR AND USE THEREOF Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) 2025-06-18 EP disclosed
WO-2025103367-A1 LIGAND-DRUG CONJUGATE, LINKER FOR CONJUGATION, AND USE THEREOF 海南先声再明医药股份有限公司 2025-05-22 WO disclosed
CN-119707835-A 2-Aminopyrimidine-5-carboxamide compounds and use thereof for the production of medicaments for the treatment and/or prophylaxis of cancer 沈阳药科大学 2025-03-28 CN disclosed
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMAC, INC. (US) 2024-12-10 US disclosed
CN-118451069-A Heterocyclic compounds 正大天晴药业集团股份有限公司 2024-08-06 CN disclosed
CN-118176195-A Pyrazolo [3,4-d ] pyrimidine-3-ketone compound and medical application thereof 正大天晴药业集团股份有限公司 2024-06-11 CN disclosed
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-03-21 US disclosed
CN-117430591-A Synthesis method of avanafil 康普药业股份有限公司 2024-01-23 CN disclosed
EP-0964864-A2 PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1999-12-22 EP disclosed
WO-1998033798-A2 PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION WARNER LAMBERT COMPANY (US) 1998-08-06 WO disclosed
US-5250548-A Treating hypertension, heart failure ABBOTT LABORATORIES (US) 1993-10-05 US disclosed
EP-0475206-A2 Angiotensin II receptor antagonists ABBOTT LABORATORIES (US) 1992-03-18 EP disclosed
EP-0188094-B1 QUINAZOLINE DERIVATIVES AND ANTIHYPERTENSIVE PREPARATIONS CONTAINING SAME AS EFFECTIVE COMPONENTS MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1992-03-18 EP disclosed
EP-0192783-B1 2-PIPERAZINOPYRIMIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1991-04-17 EP disclosed
US-4742165-A HERBICIDES MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-05-03 US disclosed
US-4734418-A Quinazoline compounds and antihypertensives MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-03-29 US disclosed
EP-0192783-A1 2-PIPERAZINOPYRIMIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1986-09-03 EP disclosed
EP-0188094-A2 Quinazoline derivatives and antihypertensive preparations containing same as effective components MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1986-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 ALDH1A1 1116/4885KDM4E 2775/4885KMT2A 3486/4885
US-20250304587-A1 WEE1 INHIBITOR, PREPARATION THEREFOR AND USE THEREOF WEE1, WEE2, NOTUM ALDH1A1 2066/4885KDM4E 1684/4885KMT2A 2959/4885
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors FGFR1, FGFR3, FGFR2 ALDH1A1 1116/4885KDM4E 2775/4885KMT2A 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.